Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
Subcutaneous Dosing Considerations Subcutaneous shots have a similar dose to intramuscular ones
Heres why patients trust us for their B12 shots: Experienced Providers : Our team has a long history of administering vitamin shots while maintaining patient comfort
The deltoid (upper arm) is also an IM site but can be harder to reach on your own
Compound Reference Data Compound: AOD-9604 CAS Number: 221231-10-3 Molecular Formula: C78H123N23O23S2 Molecular Weight: 1815.07 g/mol Sequence: YLRIVQCRSVEGSCGF (residues 177191 of human growth hormone) Synonyms: AOD9604, Anti-Obesity Drug 9604, hGH fragment 176-191 (modified) Selected Published Studies Published research on AOD-9604 consists of animal-model and in vitro studies
Weight loss, when it occurs in individuals receiving these injections, is more likely attributable to concurrent dietary modifications, increased physical activity, or other lifestyle interventions rather than the injections themselves
